title: [Inadequate vaccination coverage in a French cohort of HIV positive patients].
abstract: BACKGROUND
  HIV patients have a high rate of infectious complications. Vaccination, though less efficient in case of severe immunosuppression, can prevent some of these infections. Since 2006, new vaccine recommendations have been elaborated in France. We studied the vaccine status of HIV+ patients for influenza, Streptococcus pneumoniae, tetanus, and hepatitis A and B among an alsatian HIV+ population.
  
  
  METHODS
  From August 20, 2007 to September 15, 2007, HIV patients of the Alsace HIV center (COREVIH) were included in a prospective study, screening demographic, medical, immunovirological, and vaccination data.
  
  
  RESULTS
  Three hundred and thirty-one patients were included, 49% of whom were asymptomatic, 29% symptomatic without AIDS, 18% at AIDS stage, and no documentation for 4%. Seventy-one patients (21.4%) were vaccinated against influenza, 11 (3.3%) against Streptococcus pneumoniae, 34 against HAV (only 16.3% of patients with a negative test before), 120 against HBV (60% of patients with no serological markers before), and 186 (56.2%) against tetanus. The most frequent reasons for non-vaccination were non-proposal by physicians, lack of expected effectiveness, and fear of an immunovirological adverse effect.
  
  
  CONCLUSIONS
  Vaccination coverage for recommended vaccines of HIV infected people remains at a low level and appears sometimes inferior to the rates reached among the general French population. It is necessary to inform prescribers and HIV positive patients about the interest of vaccination.
authors.affiliation: Pôle Médecine, Service de Médecine Interne et Rhumatologie, Hôpital Louis-Pasteur, 39 Avenue de la Liberté, 68024 Colmar Cedex, France. mahsa.mohseni@ch-colmar.fr
authors.forename: M
authors.initials: M
authors.lastname: Mohseni-Zadeh
authors.forename: D
authors.initials: D
authors.lastname: Rey
authors.forename: M-L
authors.initials: ML
authors.lastname: Batard
authors.forename: G
authors.initials: G
authors.lastname: Beck Wirth
authors.forename: M-L
authors.initials: ML
authors.lastname: Partisani
authors.forename: J-M
authors.initials: JM
authors.lastname: Lang
authors.forename: Y
authors.initials: Y
authors.lastname: Hansmann
authors.forename: D
authors.initials: D
authors.lastname: Christmann
authors.forename: M
authors.initials: M
authors.lastname: Martinot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004168:Diphtheria Toxoid; D005260:Female; D005602:France; D015658:HIV Infections / Q000453:epidemiology*; D006679:HIV Seropositivity; D006801:Humans; D007252:Influenza Vaccines; D008297:Male; D008875:Middle Aged; D009042:Motivation; D010349:Patient Compliance; D022242:Pneumococcal Vaccines; D023321:Poliovirus Vaccines; D017410:Practice Guidelines as Topic; D013745:Tetanus Toxoid; D014611:Vaccination / Q000706:statistics & numerical data*; D017778:Vaccines, Combined; D014761:Viral Hepatitis Vaccines; D055815:Young Adult
chemical_list: C558158:DTPolio vaccine; D004168:Diphtheria Toxoid; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines; D023321:Poliovirus Vaccines; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D014761:Viral Hepatitis Vaccines